Similar articles for PMID: 32606050

Year	Number of Results
2020	18
2021	3

1

COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach.

Cheng F, Rao S, Mehra R. Cheng F, et al. Cleve Clin J Med. 2020 Jun 30. doi: 10.3949/ccjm.87a.ccc037. Online ahead of print. Cleve Clin J Med. 2020. PMID: 32606050 Free article.

2

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?

Sargiacomo C, Sotgia F, Lisanti MP. Sargiacomo C, et al. Aging (Albany NY). 2020 Mar 30;12(8):6511-6517. doi: 10.18632/aging.103001. Epub 2020 Mar 30. Aging (Albany NY). 2020. PMID: 32229706 Free PMC article.

3

A Review of SARS-CoV-2 and the Ongoing Clinical Trials.

Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, Wang ML, Chiou SH. Tu YF, et al. Int J Mol Sci. 2020 Apr 10;21(7):2657. doi: 10.3390/ijms21072657. Int J Mol Sci. 2020. PMID: 32290293 Free PMC article. Review.

4

SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options.

Chakraborty C, Sharma AR, Sharma G, Bhattacharya M, Lee SS. Chakraborty C, et al. Eur Rev Med Pharmacol Sci. 2020 Apr;24(7):4016-4026. doi: 10.26355/eurrev_202004_20871. Eur Rev Med Pharmacol Sci. 2020. PMID: 32329877 Free article. Review.

5

The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.

Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R. Chaccour C, et al. Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z. Trials. 2020. PMID: 32513289 Free PMC article.

6

Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19.

Dodds MG, Krishna R, Goncalves A, Rayner CR. Dodds MG, et al. Br J Clin Pharmacol. 2020 Jul 21. doi: 10.1111/bcp.14486. Online ahead of print. Br J Clin Pharmacol. 2020. PMID: 32693436

7

Designing a Network Proximity-Based Drug Repurposing Strategy for COVID-19.

Stolfi P, Manni L, Soligo M, Vergni D, Tieri P. Stolfi P, et al. Front Cell Dev Biol. 2020 Oct 6;8:545089. doi: 10.3389/fcell.2020.545089. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33123533 Free PMC article.

8

COVID-19 Drug Discovery Using Intensive Approaches.

Asai A, Konno M, Ozaki M, Otsuka C, Vecchione A, Arai T, Kitagawa T, Ofusa K, Yabumoto M, Hirotsu T, Taniguchi M, Eguchi H, Doki Y, Ishii H. Asai A, et al. Int J Mol Sci. 2020 Apr 18;21(8):2839. doi: 10.3390/ijms21082839. Int J Mol Sci. 2020. PMID: 32325767 Free PMC article. Review.

9

Analysis of the susceptibility to COVID-19 in pregnancy and recommendations on potential drug screening.

Zhao X, Jiang Y, Zhao Y, Xi H, Liu C, Qu F, Feng X. Zhao X, et al. Eur J Clin Microbiol Infect Dis. 2020 Jul;39(7):1209-1220. doi: 10.1007/s10096-020-03897-6. Epub 2020 Apr 23. Eur J Clin Microbiol Infect Dis. 2020. PMID: 32328850 Free PMC article. Review.

10

Serum albumin-mediated strategy for the effective targeting of SARS-CoV-2.

Mani Mishra P, Uversky VN, Nandi CK. Mani Mishra P, et al. Med Hypotheses. 2020 Apr 24;140:109790. doi: 10.1016/j.mehy.2020.109790. Online ahead of print. Med Hypotheses. 2020. PMID: 32353740 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed